Objectives: Despite the clear benefits of high adherence, interventions aimed at improving adherence have had mixed success. This study reviewed the evidence associated with the following adherence intervention types: functional (e.g., introducing medication reminder systems), educational interventions (e.g., improving disease and adherence education), and motivational interventions (e.g., improving social support; incentivizing/reducing barriers to adherence). MethOds: A prior systematic literature review on adherence interventions conducted by the Agency for Healthcare Research and Quality was updated focusing on interventions which had functional (e.g., making it easier for patients to remember medications), educational (e.g., increasing disease or adherence knowledge), or motivational (e.g., reducing financial barriers) components published up until November 2013. A total of 78 articles were reviewed. Results: Functional interventions were the most common (63.3% of all the studies) and about two-thirds of the interventions were significant. The effects of educational interventions (appearing in 32.9% of studies) were small; approximately half of interventions showed an effect, though the nonsignificant interventions had smaller sample sizes (n= 150 or less). Motivational interventions (10.1% of all studies) were the most consistent in their effects (all but one study reported a significant finding) but were modest with only a 2-6% increase in adherence rates. Multifaceted interventions, which most often combined functional and education components, appeared in 15.2% of studies. These interventions had the largest effect size with a third reporting at least 20% increases in adherence rates relative to controls. cOnclusiOns: The results reinforce the challenge with improving adherence among patients with chronic disease. Although it is difficult to draw firm conclusions based on the heterogeneous interventions, functional interventions produced the largest changes in adherence. Motivational interventions, particularly when they are financial, had the most consistent effects, albeit small ones. However, multi-faceted interventions (combining functional and education interventions) were the most successful of all.
Objectives: Despite consistent sexually transmitted infection (STI) screening guidelines for asymptomatic women, less than half of women age 25 and younger are being tested for chlamydia trachomatis (CT) and neisseria gonorrhea (NG). This study sought to understand how physicians determine which patients to screen and the perceived barriers to screening. MethOds: Sixty semi-structured, 45-min phone interviews were conducted from a nationally representative sample of 30 Obstetric-Gynecologists (OBGyns) and 30 Family Practitioners (FPs). Respondents were recruited if they had 5-30 years of experience and reported that they sometime, often or always perform STI testing. A thematic approach was used to analyze the data. Results: Approximately 1 in 4 FPs offer STI testing only to symptomatic patients. OBGyns were more likely to screen based solely on age. However, approximately half of all interviewees used age in conjunction with a clinical risk assessment to determine which patients to offer screening. The most frequently sited barriers to screening for STIs were: Patients not wanting the tests, Patients not seeking regular care, Parents or partners present in the room, Patient anxiety/ embarrassment, and Patient cost concerns. The majority of respondents (75%) felt lab algorithms that automated the STI testing based on screening criteria would be helpful. cOnclusiOns: Most physicians selectively offer STI screening to women based on age and a risk assessment, with patients opting-in by specifically saying they want STI screening. The adopting of automated STI testing with an opt-out option for women age 15-25 would help reduce inconsistencies in physician's test ordering, align practice with clinical guidelines, reduce stigma associated with STI testing, and increase the rate of patient acceptance by overcoming some of the barriers to screening. . Results: 102 studies were identified and 19 were included in our review. Studies were excluded if they did not employ an HIT intervention for improving medication adherence and were instead focused on monitoring or measurement of medication adherence. The included studies spanned various disease states such mental health, diabetes, asthma, hypertension, depression, cardiovascular disease and HIV/AIDS. We found that the most commonly studied HIT interventions include SMS/text messaging, telemonitoring, and electronic prescribing. Overall, we found limited data regarding the effectiveness of HIT interventions in improving medication adherence. However, interventions such as telemonitoring were found to be effective in diseases such as asthma and diabetes, while text messaging appears to be promising in HIV/AIDS and diabetes. We posit that the rapidly evolving nature of the HIT field may be a challenge in performing rigorous outcomes studies to measure endpoints such as medication adherence. But larger trials with adequate statistical power are needed so that findings are more generalizable. cOnclusiOns: Comparative effectiveness and outcomes research is a key tool to inform policy, provider and patient decision-making and we recommend additional research on Model inputs were taken from the literature. The cost inputs for r-hFSH and its urinary competitors were ex-factory prices provided by Merck Serono affiliates in Sweden. Cost inputs were limited to the cost of gonadotropin, as medical costs were assumed to be equal for r-hFSH and its competitors and would not affect the comparison. To estimate the cost per oocyte produced or embryo generated, the prices of r-hFSH and of HP-hMG were multiplied by the average dose of gonadotropin and divided by the average number of oocytes or embryos produced according to published studies.To estimate the cost per optimal chance of live birth, the cost to produce 15 oocytes was calculated. Prior studies have demonstrated that the production of 15 oocytes leads to the greatest probability of obtaining a live birth. The model outputs were age-agnostic and did not take into consideration procedural differences amongst fertility clinics, as the referenced clinical studies did not provide these details. Results: The cost per oocyte retrieved, cost per embryo generated and cost per optimal chance of live birth were each 17% less when comparing r-hFSH to HP-hMG. cOnclusiOns: r-hFSH is cost-minimising relative to HP-hMG from the perspective of cost per oocyte retrieved, cost per embryo generated, and cost per optimal chance of live birth. The analysis demonstrates the importance of considering outcomes while comparing costs, as the 'cost per vial' in isolation may be a misleading determinant of cost-effectiveness. Objectives: Rotavirus vaccination is reimbursed in Belgium since 2006 with an initial vaccine uptake in the target group > 85%. Cost-effectiveness analysis of the vaccine is presented with indirect cost gained based on the reduction of loss in productivity. Seven years later we are able to estimate this important parameter with real-world data. MethOds: The City of Antwerp collects data on absence from work of its administrative employees: reason, duration, time period (n ~ 10,000 women). We analysed the data retrospectively from 2003 to 2012, comparing the absence duration amongst mothers with a first child before and after vaccine introduction. We assumed that rotavirus infection related absenteeism was mostly seen during the epidemic period -from January to May-and involved short-duration absences (≤ 5 days). We reported the analysis overall by annual birth cohort followed over 3 years (being the risk exposure period). Finally we compared the data from June to December (i.e. outside the epidemic period) expecting no change in short-duration absenteeism overtime. Results: 2.24% of the working women are getting a first child each year (224 women). Without vaccination they spent on average 1,056 accumulated days of short-duration absence (4.7 days per mother spread over 3 years) during the epidemic period. Since the introduction of the vaccine, that number was reduced to 499 days (47% decrease). The difference between the epidemic and the non-epidemic periods per year was 192 days before the introduction of the vaccine and it was reduced to 18 days thereafter. cOnclusiOns: A reduction in absenteeism amongst working mothers with a first child of the administrative personnel of the City of Antwerp is observed since the introduction of rotavirus vaccine. This reduction can be substantial, estimated at 2.2 days gained per person on average.
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Bonnet P. O. , Roy A. , Peyronnet J. M. GE Healthcare, Wauwatosa, WI, USA Objectives: CT users are concerned about operational disruptions and aim at reducing the number of emergency requests for service. The objective of this study was to determine if proactive monitoring can help reduce unplanned downtime. MethOds: CT systems monitored using the OnWatch technology were included in the analysis. Data was collected between 2011 and 2013 to allow comparison before and after activation. Service events such as number of disruptions, average disruption duration, and average downtime per system were compared between the pre-OnWatch and post-OnWatch periods. Service events occurring within the 2-week period following OnWatch installation were excluded as the activation triggers an unusual number of events and could skew the results. Results: 136 CT systems and 3045 service events were analyzed. Though the overall number of service events increased by 19% after OnWatch activation, the average number of disruptive events (emergency customer calls) per month decreased by 13%, from 0.76 to 0.66 (p= .02). The mean duration of emergency calls was reduced by 21%, from 11.7 to 9.2 hours (p= .02). 89 out of 140 the systems (63.6%) showed an improvement in downtime. Average downtime per month for emergency calls was reduced by 32%, from 7.97 to 5.42 hours, after the adoption of OnWatch (p< .001). Using a conservative range of two to four procedures per hour and an average payment rate of $400, 2.55 hours of increased system availability per month could represent between $24,480 and $48,960 of potential additional revenue per system. cOnclusiOns: CT users value the ability of service to reduce the number of emergency events as operational disruptions and lost revenue due to downtime are genuine concerns. The results of this analysis suggest that OnWatch allows CT users to maintain workflow efficiency by turning unplanned downtime into more predictable service events.
